SYRE
Spyre Therapeutics, Inc.
$75.04
+2.66%
2026-05-08
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Key Fundamentals
Forward P/E
-23.37
EPS (TTM)
$-2.12
ROE
-31.1%
Profit Margin
0.0%
Price/Book
11.15
Beta
3.13
Market Cap
$6.33B
Avg Volume (10D)
1.1M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$76.00
60D Low
$33.59
Avg Volume
1.0M
Latest Close
$75.04
Get breakout alerts for SYRE
Sign up for Breakout Scanner to receive daily notifications when SYRE triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Spyre Therapeutics, Inc. (SYRE) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors SYRE daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. SYRE operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.